#Bioretec #Finland #Helsinki #Kustaa Poutiainen #Stephen Industries

Overview of Recent Managerial Transactions at Bioretec Ltd

On April 28, 2026, Bioretec Oy made a significant announcement regarding managerial transactions involving Stephen Industries Inc Oy, a noteworthy player in the market. This update sheds light on critical developments within the company, emphasizing the ongoing transformation in orthopedic care through its innovative technologies.

Details of the Transactions

The report specified that the transactions were executed by Kustaa Poutiainen, a member of the Board, associated with Stephen Industries Inc Oy, which is recognized under the legal entity identifier (LEI) 7437008736AG7HY51K13. The notification highlighted an initial report regarding the transactions, with the relevant reference number being 153706/4/4. The date of the transaction was declared as April 24, 2026, and it involved share subscriptions outside of a trading venue.

The transactions were detailed as follows:
1. Volume: 322,617,824 units at a price of 0.01 EUR per unit.
2. Volume: 24,196,337 units at a price of 0 EUR.

Aggregating these transactions revealed a total volume of 346,814,161 shares with a weighted average price of 0.0093 EUR.

Innovative Advancements by Bioretec

Bioretec stands at the forefront of orthopedic solutions with its fully biodegradable implant technologies. The company has developed specialized competencies in enhancing bone growth and facilitating fracture healing. Their aim is to transform traditional orthopedic care into a more patient-friendly process by utilizing innovative materials and technologies.

One of their groundbreaking product lines, RemeOs™, utilizes advanced magnesium alloy and hybrid composites. These implants not only provide structurally sound support during recovery but are also absorbed by the body, reducing the need for subsequent removal surgeries and minimizing complications for patients.

The RemeOs line received market authorization in the U.S. in March 2023, while CE mark approval in Europe followed in January 2025, underscoring Bioretec's commitment to market expansion and compliance with stringent regulatory standards.

Equally impressive is the Activa product range, consisting of bioabsorbable orthopedic implants formulated from a unique self-reinforced PLGA material. Both the RemeOs and Activa lines are approved for use in a variety of medical applications, signaling Bioretec’s comprehensive approach to addressing diverse patient needs across demographic categories.

Conclusion

Bioretec's recent managerial transactions signify strategic movements that align with its vision of pioneering orthopedic treatments that emphasize healing through absorption. The continuous innovation within their product lines not only showcases their leadership in the market but also enhances the overall quality of patient care. By embracing a model that prioritizes patient outcomes, Bioretec Ltd is poised to redefine the future of orthopedic surgery.

To stay updated with Bioretec's advancements and strategic decisions, visit their official website at www.bioretec.com.

For further inquiries regarding these transactions, Tuukka Paavola, the Chief Financial Officer, can be contacted at +358 50 386 0013.